Kornimate/medical-research-clean huggingface dataset:
nursing care in threat of preterm birth

Conditions: Nursing Caries

Summary: relaxation-focused nursing care which is formed by using these two models is composed of; positive language, positive environment and reducing stressors. relaxation-focused nursing care, which is thought to have an effect on delaying birth, consists of four stages as a two-day program.in this study, it is aimed to determine the effect of relaxation-focused nursing care on stress level, cortisol level and birth week.

preterm birth is seen in 7-12% of all pregnant women and according to estimations about 15 million infants are delivered each year. preterm birth is an extremely important problem in terms of its effects on newborn's health, mother's health, community and economy. preterm birth causes the newborn chronic pulmonary disease; gastrointestinal, immunologic, central nervous system, auditory and visual problems; long-term motor and cardiovascular system diseases; and cognitive, visual, behavioral disorders. while preterm birth causes the women postpartum anxiety, stress and depression; it also leads to newborn intensive care costs, long-term complex health care needs for families and community and has serious consequences for public service sector such as health insurance, education, other social support systems and economy. some factors initiate preterm birth, whereas 70-80% of them start spontaneously, remaining 20-30% has iatrogenic origin. it is reported that there is no known and effective treatment for preterm birth. it is reported in literature that stress which is one of the risk factors of preterm birth, causes preterm birth. if stress causes threat of preterm delivery, reducing stress may delay preterm birth and the complications of preterm birth on newborn and mother's health and also its economic and social burden can be reduced. national and international studies related to the effect of coping with stress on threat of preterm birth are lacking. it is thought that preterm birth can be prevented in women with threat of preterm birth through developing mechanisms to cope with stress and reducing stressors. since nurse provides 24-hour care for woman diagnosed with the threat of preterm birth, the nursing care may be effective in this aspect.

Eligibility criteria:
inclusion criteria: * to be diagnosed with tpb, * to be over 18 years of age, * to know turkish and * to agree to participate in the research. exclusion criteria: * diagnosis of emr, * multiple pregnancy, * admission to hospital with vaginal bleeding, * psychiatric, chronic and pregnancy-related disease developing, * to want to quit the study at any stage after agreeing to participate in the study, and * delivery at any stage after the data collection process has been completed after agreeing to participate in the trial.

Keywords: relaxation
an observational study of avastin (bevacizumab) in patients with metastatic colorectal cancer: continued avastin plus chemotherapy after first progression in clinical practice

Conditions: Colorectal Cancer

Summary: this local, non-interventional, cohort study of patients with metastatic colorectal cancer (mcrc) will prospectively collect data from standard clinical practice of second-line treatment with chemotherapy plus avastin (bevacizumab). there will be no additional diagnostic or therapeutic procedures required by this study, apart from those performed in everyday clinical practice for second-line treatment of mcrc in croatia.


Eligibility criteria:
inclusion criteria: * written informed consent * age \>/=18 years * metastatic colorectal cancer (mcrc) previously treated with systemic treatment for advanced disease containing avastin and chemotherapy; first-line avastin received according to the summary of product characteristics (smpc) * first line progression-free survival (pfs) \>6 months * eligible for second-line chemotherapy regimen * period between first progression and start of second line treatment with avastin and chemotherapy \</=6 weeks exclusion criteria: * contraindications, warnings and precautions for use specified in the avastin smpc
a trial to compare the outcome of localised varicosity compression for 24 hours and 5 days after foam sclerotherapy to truncal varices

Conditions: Varicose Veins

Summary: the purpose of this study is to compare the results of foam treatment of varicose veins (foam sclerotherapy) in patients who wear compression bandages for 24 hours or 5 days after treatment.


Eligibility criteria:
inclusion criteria: * proven truncal venous incompetence (of \>1 second duration) on venous duplex scanning. (great saphenous vein (gsv), small saphenous vein (ssv), anterior accessory thigh vein (aatv) or other major tributary). * agreed preference for foam sclerotherapy treatment. * signed consent form agreeing to be part of the trial. exclusion criteria: * total deep venous reflux. * known allergy to liquid sclerosant. * pregnancy or breast feeding. * arterial disease.

Keywords: varicose veins foam sclerotherapy compression bandaging duration
tsi and its relationship with graves' disease relapse

Conditions: Graves Disease; Immunoglobulin; Anti-Thyroid Antibodies Disorder

Summary: the goal of this observational study is to determine the role of tsi, as well as clinical signs and thyroid function tests in predicting graves' disease (gd) relapse after withdrawing anti thyroid drug (atd). the main questions it aims to answer are: 1. to investigate the serum tsi concentration in patients with gd undergoing maintenance-dose atd. 2. to determine an optimal cut-off of tsi level for predicting gd relapse. 3. to determine the role of tsi in predicting graves' disease relapse after withdrawing atd.

retrospective follow-up study of patients with hyperthyroidism due to graves' disease, treated at the endocrine outpatient clinic of medic medical center, ho chi minh city from january 2000 to april 2021. tsi was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician). atd withdrawal would be planned when patients achieved euthyroid status clinically with normal ft4 tests for at least 3 months with minimal dose of atd. the decision was also based on tsi concentration, goiter's characteristics and parenchymal vascularity on doppler ultrasound.

Eligibility criteria:
inclusion criteria: * patients diagnosed with hyperthyroidism due to graves' disease according to the criteria of the japan thyroid association. * tsi: measured during the course of treatment when planning to stop medication (normal ft4 at maintenance-dose of atd) methimazole (mmi): at doses of ≤10 mg. propylthiouracil (ptu): at doses of ≤200 mg. exclusion criteria: * hyperthyroidism due to other causes * patients who were intolerant to atd or had serious side effects with atd. * tsis were measured in pregnancy. * patients treated with surgery or radioactive iodine.

Keywords: tsi recurrent graves' disease graves' ophthalmopathy treatment duration anti-thyroid drug cut-off
blood biomarker in early parkinson's disease

Conditions: Parkinson Disease

Summary: currently, there are no cures or disease modifying therapies for parkinson's disease (pd). this is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. the identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. in this study, we are testing a blood biomarker for pd. several detection parameters will be assessed through enrollment of parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.


Eligibility criteria:
inclusion age matched to pd patient parkinson's disease patients: * 50 years and older * pd patient who is seen at the duke movement disorders center * early pd diagnosis (hoehn and yahr scale ≤ 3) * non-smoking * no cancer treatment in the last 5 years * able to read and speak english healthy control participants: * 50 years and older * non-smoking * no cancer treatment in the last 5 years * able to read and speak english exclusion criteria: parkinson's disease patients: * known additional neurological disease * clinical trial intervention within the last 6 months healthy control participants: * neurological degenerative diseases (such as parkinson's, alzheimer's or huntington's) * clinical trial intervention within the last 6 months

Keywords: blood biomarker parkinson's disease
frankfurt thrombophilia registry

Conditions: Venous Thromboembolism

Summary: consecutive patients with acute or previous venous thromboembolism are enrolled in this registry. using a standardized questionnaire, clinical data detailing venous thromboembolism and contributing vte risk factors are recorded. results of technical and laboratory investigations including screening for thrombophilic disorders were additionally entered into the database.


Eligibility criteria:
inclusion criteria: * acute or previous vte exclusion criteria: * none

Keywords: assess prevalence thrombophilia common vte risk factors patients
biomechanical relationship between trunk flexion and mouth opening: pilot study

Conditions: Hamstring Injury; Temporomandibular Joint Disorders; Stretch

Summary: the aim of the present study is to analyze if there is a biomechanical relationship between trunk flexion and buccal opening and to observe if there is an improvement of trunk flexion by performing the "sit and reach" test when stretching the masticatory muscles.

the study design is made up of a double-blind clinical trial with 60 participants randomly divided into two groups of 30 people each (treatment group and control group). basal measurements of the mouth opening were taken with a vernier caliper and the trunk flexion measurements were taken by means of the "sit and reach" test. these measurements were carried out again after the intervention, which consisted of self-stretching of the masticatory muscles for the treatment group and an occlusion of the mouth for the control group. in the results there was an increase in the trunk flexion compared to the initial values in both groups (treatment group 2.8 (1.51), control group 1.97 (2.31) and this increase was greater in the treatment group even though the difference with the control group was not statistically significant. therefore, the stretching of the masticatory muscles does not cause an immediate increase in the degree of trunk flexion measured by the "sit and reach" test. as a consequence, we cannot confirm the existence of a biomechanical relationship between trunk flexion and mouth opening.

Eligibility criteria:
inclusion criteria: 1. being between 18 and 26 years old (both included). 2. having signed the consent form. 3. being able to introduce three knuckles of the non-dominant hand between the incisors. exclusion criteria: 1. having a musculoskeletal injury in the lower extremity and / or in the jaw. 2. being in the process of receiving physiotherapy treatment and / or having undergone any odontologic or maxillofacial surgery in the last month. 3. having suffered dislocations, painful clicks or being diagnosed with some type of temporomandibular joint (tmj) dysfunction. 4. having hypermobility in the temporomandibular joint (tmj) that is, the measurement of the buccal opening being greater than 60 mm.
a feasibility study to evaluate the effect of the electronic patient visit assessment on pain and quality of life for patients with head and neck cancer (hnc)

Conditions: Head and Neck Cancer

Summary: this randomized, non-blinded, phase 0/i study will assess the feasibility of conducting a large randomized clinical trial to evaluate the efficacy of the epva to improve pain management and hrqol in hnc. thirty participants undergoing radiation therapy (rt) (with or without chemotherapy) will be randomized to: 1) epva intervention or 2) usual care. the intervention consists of participants completing the epva every other week during radiation therapy (rt), then weeks 4, 12, and 24 after end of rt. automated reports of epva data, including pain reports and patient-reports of pain medications, will be sent to providers to inform their clinical decisions.


Eligibility criteria:
inclusion criteria: to be eligible to participate in this study, an individual must meet all of the following criteria: 1. histologically diagnosed hnc 2. undergoing rt with or without chemotherapy, 3. english speaking, 4. aged 18 years or older. exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: 1. unable to attend scheduled appointment due to geographical, social or mental reseaons, 2. in the opinion of the investigator, is unable or unlikely to comply fully with the study requirements or procedures for any reason (e.g. cognitve or physical impairment).
combined use of pulsed dye laser and topical antiangiogenic agents for treatment of port wine stain birthmarks

Conditions: Port Wine Stain

Summary: the researcher want to improve port wine stain (pws) therapeutic outcome in response to laser therapy. the researcher want to determine whether the combined use of pulsed dye laser (pdl) therapy and topical tacrolimus or pimecrolimus will improve pws therapeutic outcome.

both topical agents inhibit nuclear factor of activated t-cells (nfat) which blocks the calcineurin/nfat pathway inhibiting endothelial cell proliferation and angiogenesis, which could be very useful in preventing pws recanalization. the combined use of pdl to induce pws blood vessel injury, and topical antiangiogenic agents to prevent pws blood vessel angiogenesis and recanalization after laser therapy, will improve pws lesion blanching.

Eligibility criteria:
inclusion criteria: * 16 years of age and older * have pws suitable for comparison testing as determined by the study doctor exclusion criteria: * less than 16 years old * are pregnant * have skin cancer * currently taking immunosuppressive or steroids or photosensitizing drugs * current participation in any other investigational drug evaluation * concurrent use of known photosensitizing drugs

Keywords: birthmark pws
effectiveness of treadmill walk on chronic low back pain

Conditions: Chronic Low Back Pain

Summary: chronic low back pain is a common health problem with a multifactorial impact on core muscle function as well as causing pain, functional disability and decrease in quality of life, this occur due to the reduction in the physical activity level of the individual causing atrophy and inhibition of the core muscle affecting the stability of the spine

there are several approaches and methods of treating chronic low back pain (clbp) ranging from education, exercise, electrotherapy and manual therapy; to alternative treatment such as acupuncture, yoga and chiropractic. among the above mention treatment exercise, manual therapy and education are the most frequently utilize for the management of clbp. the general recommendation for individual with clbp is to remain active as possible and this can be achieve through exercise. evidence shows that active treatment in form of strengthening exercise of the abdominal and back muscles, core stabilization exercise, coordination exercise and aerobic exercise leads to significant reduction in pain and functional disability in patients with clbp. a number of researches have been focusing on core stability exercise, which is an effective way of recruiting the core muscle (including the abdominal, back, pelvic and hip muscles) that leads to the optimal force production, control of lumbopelvic-hip movement and load transfer from the spine to the pelvis and the lower extremities. the core stabilization exercise has been establish to activate and strength the deep core muscles, but researches are now focusing on the exercise that can be able to activate the core muscles as well as increase the overall health status of the individual

Eligibility criteria:
inclusion criteria: * male and females between the age of 18 to 65years * participants attending usmanu danfodiyo university teaching hospital, sokoto state specialist hospital and orthopedic hospital * participants with chronic non-specific low back pain exclusion criteria: * participants with current low back pain for less than 12 weeks * participants with cognitive and visual impairment * participants with other co-morbidities ( systemic disease, carcinomas, organ disease) * participants with other neurological findings such as loss of sensation, radiculopathy, parenthesis * body mass index of more than 30 kilogram per meter square * participants who are pregnant * participants who had spinal surgery

Keywords: treadmill walk
treatment of oral lichen planus with paeoniflorin and photodynamic therapy

Conditions: Oral Lichen Planus

Summary: oral lichen planus (olp) is a common chronic inflammatory disease of the oral mucosa and is considered a precancerous condition. it is characterized by white reticular changes in the oral mucosa, which can progress to erosions and cause pain in severe cases. the pathogenesis of olp is still unclear, but it is believed to be a t-lymphocyte-mediated autoimmune disease. currently, only symptomatic treatments are available, and there is no definitive cure. in this project, we plan to use tcm differentiation to categorize olp patients and conduct a randomized controlled clinical trial to demonstrate the enhanced therapeutic effect of paeoniflorin combined with photodynamic therapy for olp. the implementation of this project will provide new insights into the clinical management of olp, improve our understanding of the treatment mechanisms, and have important theoretical and clinical implications.

paeoniflorin, a compound extracted from the traditional chinese medicine, has anti-inflammatory and immunomodulatory effects. photodynamic therapy is a novel local treatment approach, where photosensitizers selectively target and destroy diseased cells. both treatments have shown efficacy in treating olp when used individually.

Eligibility criteria:
inclusion criteria: * patients with oral lichen planus * male or female patients older than 18 years of age * patients willing to participate with signed informed consent. exclusion criteria: * pregnant or lactating * had serious systemic diseases of the heart, lung, liver, and kidney, or had tumors * were unwilling to participate in the experiment.

Keywords: oral lichen planus integrated chinese and western medicine total glucosides of paeony photodynamic therapy
costs & outcomes of hospitalization/treatment with levalbuterol & albuterol in asthma or chronic obstructive pulmonary disease (copd) subjects

Conditions: Asthma; COPD

Summary: an analysis of the costs and outcomes associated with hospitalization and treatment of levalbuterol versus racemic albuterol in subjects with asthma and copd.

this was a randomized, open-label study evaluating clinical and pharmacoeconomic outcomes in hospitalized patients with asthma or copd who have been admitted due to an exacerbation of their disease and required further treatment with a beta2-adrenergic agonist. approximately 430 patients were randomized and enrolled. patients were then followed during their hospitalization. once discharged, patient status was assessed via telephone interview 30 days after discharge. this study was previously posted by sepracor inc. in october 2009, sepracor inc. was acquired by dainippon sumitomo pharma., and in october 2010, sepracor inc's name was changed to sunovion pharmaceuticals inc.

Eligibility criteria:
inclusion criteria: * male and female subjects must be at least greater than or equal to 18 years of age at the time of consent. * subjects must have history of asthma or copd for at least 6 months prior to hospitalization. * subjects must have been hospitalized due to an exacerbation of their disease and required further treatment with a nebulized beta2-adrenergic agonist. * subjects must have an oxygen saturation level greater than or equal to 90% with greater than or equal to 40% face mask supplemental oxygen. exclusion criteria: * subjects who are likely to be in the intensive care unit (icu) or critical care unit (ccu). * based upon history or physical exam in the ed or clinic, subjects with known or suspected cause of pulmonary symptoms other than asthma or copd, such as pneumonia, pulmonary embolism, cystic fibrosis, or angioedema. subjects with chf that are admitted with a primary admission diagnosis of copd are not excluded. * female subjects who are pregnant or breast feeding. * subjects who have participated in an investigational drug study within 30 days of study entry or have previously participated in the current trial. * subjects who are planning to receive elective surgical procedures during the 30 day period after hospital discharge.

Keywords: asthma copd chronic emphysema chronic bronchitis
diaphragmatic reinnervation of tetraplegic patients with respiratory insufficiency

Conditions: Tetraplegia

Summary: this study evaluates the diaphragmatic reinnervation by inferior laryngeal nerve in tetraplegic patients with ventilatory insufficiency.


Eligibility criteria:
inclusion criteria: * tetraplegia c3-c4 * respiratory insufficiency exclusion criteria: * pm

Keywords: tetraplegia reinnervation phrenic nerve
effects of labetalol on nicotine administration in humans - 14

Conditions: Tobacco Use Disorder

Summary: the purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine

the purpose of this study is to determine whether labetalol, an alpha and beta adrenergic blocker, will block the subjective and physiological effects of intravenously administered nicotine in humans. a total of 12 subjects will participate in the double blind placebo controlled, outpatient study. subjects will have 3 separate experimental sessions 3-9 days apart. on each of the experimental sessions, a single oral dose of low (100mg) or high dose of labetalol (200mg ), or placebo will be administered. two hours after labetalol or placebo treatment, subjects will receive 15 variance grams nicotine base/kg intravenously. several physiological endocrine and subjective measures will be obtained during the sessions. we propose that blockage of adrenergic receptors by labetalol will significantly block the physological and subjective effects of nicotine.

Eligibility criteria:
inclusion criteria: male/female, aged 21-55 years with a smoking history of at least 1 pack of cigarettes daily for at least 1 year. in good health as verified by medical history, screening examination, and screening laboratory tests. exclusion criteria: history of heart disease, peripheral vascular disease, copd, any other medical condition which physician investigator deems inappropriate for subject participation. pregnant or lactating or not using adequate birth control methods. use of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics and recent psychiatric history). chronic use of systemic steroids or antihistamines. abuse of alcohol or any other recreational or prescription drug. regular use of any other tobacco products, including smokeless tobacco and nicotine products.